New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC

An 85-year-old man with advanced metastatic castration-resistant prostate cancer and progression after 8 cycles of 177 Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) received 1 cycle of 161 Tb-PSMA RLT. This one administration of 6.5 GBq 161 Tb-PSMA-617 resulted in impres...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2023-05, Vol.48 (5), p.433-434
Main Authors: Rosar, Florian, Maus, Stephan, Schaefer-Schuler, Andrea, Burgard, Caroline, Khreish, Fadi, Ezziddin, Samer
Format: Article
Language:English
Subjects:
Aged, 80 and over
Heterocyclic Compounds, 1-Ring - therapeutic use
Humans
Lutetium - therapeutic use
Male
Positron Emission Tomography Computed Tomography
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant - diagnostic imaging
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - radiotherapy
Radioisotopes - therapeutic use
Terbium
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An 85-year-old man with advanced metastatic castration-resistant prostate cancer and progression after 8 cycles of 177 Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) received 1 cycle of 161 Tb-PSMA RLT. This one administration of 6.5 GBq 161 Tb-PSMA-617 resulted in impressive partial remission with a PSA decline by 53.4% (from 474 to 221 ng/mL) and a concomitant decrease in tumor burden on PSMA PET/CT imaging. The presented case provides stunning initial evidence of the therapeutic potential of 161 Tb-PSMA RLT in metastatic castration-resistant prostate cancer, even in patients progressing after extensive 177 Lu-based RLT. 161 Tb-labeled PSMA ligands may thus offer a promising alternative to standard PSMA RLT.
ISSN:0363-9762
1536-0229
DOI:10.1097/RLU.0000000000004589